Skip to content
Open in App
Aclaris Therapeutics Inc logo

Aclaris Therapeutics Inc

web2

Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing investigational m...

Symbol · ACRS
Company profile

About

Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing investigational medicines for immunological and inflammatory diseases, with research programs targeting conditions involving abnormal immune responses. Its development pipeline includes modzatinib, also known as ATI-2138, an oral inhibitor being investigated for lichen planus, an inflammatory condition affecting the skin and mucous membranes. The company is also developing ATI-052, an investigational antibody designed to act on two immune signaling pathways. Aclaris conducts clinical studies to evaluate the safety and potential effectiveness of its drug candidates. These programs remain subject to clinical development and regulatory review, rather than representing established commercial treatments.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNasdaqPrimary symbol: ACRS
Expert coverage

1 expert evaluated Aclaris Therapeutics Inc.

Orbitrum research

Experts evaluating Aclaris Therapeutics Inc

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment